By News Desk  @bactiman63 Biotechnology company, Ridgeback Biotherapeutics, announced recently that the U.S. Food and Drug Administration (FDA) approved EbangaTM for the treatment of Ebola. Ebanga...

Today, the U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola...

An investigational treatment for Ebola virus disease will receive advanced development support from the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness...

New research by the Centers for Disease Control and Prevention (CDC) shows two investigational Ebola treatments being used in the ongoing outbreak in eastern Democratic Republic of the Congo (DRC) are...

Since August 2018, an Ebola Virus Disease outbreak has raged in eastern Democratic Republic of the Congo, their 10th outbreak and the 2nd largest ever. Earlier this week the disease spilled over into neighboring...

The investigational Ebola treatment mAb114 is safe, well-tolerated, and easy to administer, according to findings from an early-stage clinical trial published in The Lancet. Eighteen healthy adults...

There is a new medication that in one dose successfully protected nonhuman primates against a lethal infection of all strains of the deadly Ebola virus. The findings are now available in Cell Host &...

The Democratic Republic of Congo has approved the use of four experimental Ebola treatments to manage the ongoing outbreak in the east of the country. At least 59 people have died, with 102 cases diagnosed...

A first-in-human trial evaluating an experimental treatment for Ebola virus disease has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland. The Phase 1 clinical trial is...

More than 11,000 people died during the Ebola outbreak in West Africa from 2013-16, demonstrating both the deadly nature of the virus and the limitations of the medication used to fight it. Now, University...